- ‘Cancer-Shattering’ Method Targets Non-Coding Sequences to Eradicate Brain Tumors
- What is HIV Post-Exposure Prophylaxis (PEP)?
- Moderna Team Detects No Uptake of mRNA-LNPs in Muscles at Injection Site
- Vitamin B5 Found to Promote Cancer Growth
- Harmful Chemical D5 Found in Common Hair Care Products
- Antibiotics Unveiled as Potential Life Extenders Aiding Healthier Aging
Utrecht University and Hebo Pharm Cooperation on COVID-19
Utrecht University and Hebo Pharm Cooperation on COVID-19. Hebo Pharm and Utrecht University jointly announced a license agreement with AbbVie for the COVID-19 antibody and initiated clinical trials.
Global biopharmaceutical companies in the clinical development stage and Platinum Pharmaceuticals (stock code: 02142.HK) and Utrecht University jointly announced today that they have authorized AbbVie to prevent and treat COVID-19 and related coronaviruses. The source neutralizing antibody ABBV-47D11 has started a phase I clinical trial. AbbVie will first carry out this clinical research project in the United States and expand to Europe.
The H2L2 fully human transgenic mouse platform of Hebo Medicine can quickly discover and develop effective drug candidates. Among them, the cross-reactivity and neutralization properties of ABBV-47D11 make it an ideal drug candidate this time. The antibody targets the conserved region of SARS-CoV-2. Collaborative preclinical studies have so far shown that antibodies against this target have good therapeutic potential for the current epidemic, including a series of potential escape mutations.
The signing of the license agreement will help promote the development of ABBV-47D11. In preclinical studies, the antibody showed the potential to block SARS-CoV-2 and SARS-CoV-1 infections. According to the equity introduction agreement, AbbVie will be responsible for the clinical research of ABBV-47D11. If the clinical development is successful, it will be responsible for the global production and commercialization process.
At the same time, AbbVie will pay Hobo Pharma and Utrecht University a one-time equity transfer fee and phased fees for franchise development, supervision and sales, as well as tiered royalties on net commercial sales for the antibody rights. Erasmus University Medical Center participates in the basic science research and does not participate in the signing of the authorization agreement. The remaining terms were not disclosed.
The Phase I clinical trial will be a randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of ABBV-47D11 in a single-dose climb in COVID-19 adult hospitalized population dynamics. The trial will be divided into three dose groups to test 24 patients distributed in multiple research bases around the world. The primary endpoint is to evaluate the adverse events related to the study drug and establish multiple secondary endpoints. For more details about the trial, please click to read the original text
Dr. Wang Jinsong, the main founder, executive director, chairman and CEO of Hebo Medicine, said: “The rapid progress of this project depends on the advantages of our excellent R&D team, university partners, and Hebo Medicine’s fully human antibody discovery platform. As well as partner AbbVie’s world-leading expertise in the development of antibodies and antiviral drugs. With the development of the clinical trials of this project, we hope to provide a new treatment plan for the current epidemic.”
About Hebo Pharmaceutical
Hebo Pharmaceutical is a Chinese biopharmaceutical company in the clinical development stage. The company focuses on the research and development of innovative drugs for tumor immunity and immune diseases, and expands its drug research and development pipeline through independent research and development, joint development and diversified cooperation models.
Hebo Medicine uses its patented two fully human antibody transgenic mouse platforms (Harbour Mice®) to develop fully human monoclonal antibodies and heavy chain antibodies (HCAb), and builds HBICE™ technology based on HCAb to develop immune cell connections Organ bispecific antibodies. These two platforms are used to produce fully human monoclonal antibodies and heavy chain antibodies (HCAb), respectively. At the same time, the company also licenses technology platforms to companies and academic institutions. Hobo Pharma has operations in Cambridge, Massachusetts, Rotterdam, Netherlands, Suzhou, China, and Shanghai, China.
About Utrecht University
Founded in 1636, Utrecht University is one of the largest research universities in Europe, with 30,000 students and more than 6,000 faculty members. Utrecht University ranks in the forefront of many international rankings. The school cultivates future leaders through the highest quality innovative education and is committed to conducting groundbreaking research to solve major global problems. The school’s cooperative culture provides fertile ground and cradle for fostering innovation, cultivating new insights, and having an impact on society.